AI Analysis | Feedback

An "Olympus for micro-medical endoscopes."

A "ZEISS for custom micro-optics."

AI Analysis | Feedback

• Micro-Optics and Optical Systems: Precision Optics designs and manufactures custom, high-precision miniature and micro-optics assemblies and systems for various demanding applications.
• Medical Endoscopes and Imaging Systems: The company develops and produces advanced optical systems, including both reusable and high-volume disposable endoscopes and other medical imaging devices.
• Defense and Aerospace Optical Components: Precision Optics provides specialized optical components and systems tailored for critical defense and aerospace applications.

AI Analysis | Feedback

Precision Optics (symbol: POCI) primarily sells its products and services to other companies (Business-to-Business or B2B) rather than directly to individuals.

While Precision Optics' SEC filings (such as their annual 10-K reports) indicate significant revenue concentration from a few major customers (e.g., one customer accounted for 30% of revenue and another for 18% in fiscal year 2023), the company does not publicly disclose the specific names of these major customer companies. This is common practice in many industries due to confidentiality agreements with their OEM (Original Equipment Manufacturer) partners.

Based on their public disclosures, Precision Optics' major customers are primarily:

• Original Equipment Manufacturers (OEMs) in the Medical Industry: These customers integrate Precision Optics' miniature optical systems, micro-optics, and medical imaging modules into their own medical devices, particularly for applications in endoscopy, ophthalmology, and other surgical areas.
• Government Prime Contractors and OEMs in the Defense Industry: Precision Optics supplies specialized optical components and systems for defense and security applications.
• OEMs in the Industrial and Commercial Sectors: To a lesser extent, the company also serves manufacturers in various industrial and commercial markets requiring precision optical solutions.

AI Analysis | Feedback

null

AI Analysis | Feedback

Dr. Joseph N. Forkey President / CEO

Dr. Joseph Forkey was appointed Chief Executive Officer, President, and Treasurer of Precision Optics Corporation in February 2011. He brings over thirty years of experience in inter-disciplinary optical technology within the medical device and defense/aerospace sectors. Dr. Forkey joined Precision Optics in 2003, initially serving as Chief Scientist from 2003 to 2006, then as Executive Vice President and Chief Scientific Officer from 2006 to 2011. He is responsible for the company's overall strategic direction, resource management, and driving growth, including through targeted acquisitions.

Wayne M. Coll Chief Financial Officer

Wayne M. Coll was appointed Chief Financial Officer and Secretary in June 2023. He has over 30 years of senior financial executive experience, primarily in medical device-based businesses, including publicly traded companies. His expertise encompasses driving business models, executing strategic mergers and acquisitions, and managing access to capital markets. Prior to Precision Optics, Mr. Coll served as CFO for Flowonix Medical Incorporated, Micron Solutions (a publicly traded medical devices and contract manufacturer), Keystone Dental, Modern Dental Laboratory USA, and Pluromed, a medical device company that was acquired by Genzyme/Sanofi. He also spent nearly 20 years at National Dentex Corporation, a publicly traded dental laboratory, including five years as CFO.

Joseph Traut Chief Operating Officer

Joseph Traut was appointed Chief Operating Officer, effective October 1, 2025. He brings extensive experience in operations and manufacturing to the company.

Divaker Mangadu President of Ross Optical Division

As President of Ross Optical Industries, a division of Precision Optics Corporation, Divaker Mangadu oversees all aspects of sales & marketing, supply chain, manufacturing, and quality assurance. He has over 25 years of experience in Optics sourcing and manufacturing. Mr. Mangadu is a skilled mechanical engineer and an entrepreneurial leader in precision manufacturing, working with primes and OEMs to minimize supply chain risk and cost.

Jonathan Everett VP of Engineering

Jonathan Everett serves as the Vice President of Engineering at Precision Optics.

AI Analysis | Feedback

1. Supply Chain Vulnerabilities and Geopolitical Risks: Precision Optics faces significant risks due to its reliance on a limited number of overseas suppliers for critical raw materials, such as precision-grade optical glass and CMOS image sensors, with some suppliers located in China. Potential changes in U.S. tariff policies and related trade actions could disrupt their international supply chain, increase costs, and weaken their competitive position.
2. Ongoing Financial Losses and Funding Needs: The company has a history of losses and may continue to incur losses in the near term. For the fiscal year ended June 30, 2024, Precision Optics reported a net loss of $3.0 million and an operating loss of $2.7 million. Over the last twelve months, the company produced an earnings before interest and tax (EBIT) loss of approximately US$5.6 million and bled US$3.8 million in negative free cash flow, indicating a potential need to raise additional funds.
3. Customer Concentration: Precision Optics is heavily reliant on a small number of customers. The loss of any major customer could lead to a significant decline in the company's revenues.

AI Analysis | Feedback

AI Analysis | Feedback

AI Analysis | Feedback

Precision Optics Corporation (POCI) anticipates several key drivers for its future revenue growth over the next two to three years:

1. Expansion of Systems Manufacturing Business: A primary driver of expected revenue growth is the significant expansion of Precision Optics' systems manufacturing business, particularly in its aerospace and single-use cystoscope production programs. The company forecasts this segment to increase by more than 75% in fiscal year 2026, building on a trend seen in fiscal 2025 where revenue from this business nearly tripled.

2. Growth in Single-Use Endoscope Products: Strategic investments in single-use endoscope technology are expected to lead to substantial long-term revenue growth in the production business. The company has recently secured its first production orders for two single-use programs, including an ophthalmic product, validating this growth strategy.

3. Strengthening Product Development Pipeline and Customer Base Expansion: Precision Optics' engineering pipeline continues to strengthen, driven by marketing efforts around its Unity platform and an expanding outreach focused on broadening its customer base. The company projects a modest recovery in product development revenue for fiscal year 2026, noting that product development directly fuels increases in its production business.

4. Increased Production Capacity and Enhanced Manufacturing Efficiencies: The company is focused on improving manufacturing yields, better pass-through of tariffs, and eliminating low-margin revenue. These operational improvements, along with increased production capacity for its aerospace program and the appointment of a new Chief Operating Officer, are expected to support higher production volumes and contribute to overall revenue growth by improving profitability and efficiency.

5. Securing Long-Term Contracts: Precision Optics has secured multi-year agreements with a top-tier aerospace company and a surgical robotics company. These long-term contracts provide increased visibility and confidence in sustained future revenue growth, underpinning the expansion in its systems manufacturing business.

AI Analysis | Feedback

Share Issuance

• Precision Optics raised approximately $2.3 million through a private placement in June 2023.
• An additional $1.4 million was raised through the sale of common stock in August 2024.
• The number of shares outstanding for Precision Optics increased by 16.67% in 2025, 20% in 2023, and 25% in 2022.

Inbound Investments

• Precision Optics secured a $2,600,000 term loan and a $1,250,000 revolving line of credit from Main Street Bank.
• As of June 30, 2024, $1,000,000 was outstanding on the line of credit.
• As of September 30, 2024, the company had outstanding borrowings of $500,000 on its line of credit, with an additional $750,000 available for use.

Capital Expenditures

• In the 12 months leading up to November 4, 2025, capital expenditures were approximately $227,209.
• For the quarter ended September 30, 2024, cash used in investing activities was $28,099.